Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo
- PMID: 20221584
- PMCID: PMC4306708
- DOI: 10.1007/s00125-010-1692-1
Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo
Abstract
Aims/hypothesis: AMP-activated protein kinase (AMPK) is an evolutionarily conserved enzyme and a target of glucose-lowering agents, including metformin. However, the precise role or roles of the enzyme in controlling insulin secretion remain uncertain.
Methods: The catalytic alpha1 and alpha2 subunits of AMPK were ablated selectively in mouse pancreatic beta cells and hypothalamic neurons by breeding Ampkalpha1 [also known as Prkaa1]-knockout mice, bearing floxed Ampkalpha2 [also known as Prkaa2] alleles (Ampkalpha1 ( -/- ),alpha2( fl/fl ),), with mice expressing Cre recombinase under the rat insulin promoter (RIP2). RIP2 was used to express constitutively activated AMPK selectively in beta cells in transgenic mice. Food intake, body weight and urinary catecholamines were measured using metabolic cages. Glucose and insulin tolerance were determined after intraperitoneal injection. Beta cell mass and morphology were analysed by optical projection tomography and confocal immunofluorescence microscopy, respectively. Granule docking, insulin secretion, membrane potential and intracellular free Ca(2+) were measured with standard techniques.
Results: Trigenic Ampkalpha1 ( -/- ),alpha2( fl/fl ) expressing Cre recombinase and lacking both AMPKalpha subunits in the beta cell, displayed normal body weight and increased insulin sensitivity, but were profoundly insulin-deficient. Secreted catecholamine levels were unchanged. Total beta cell mass was unaltered, while mean islet and beta cell volume were reduced. AMPK-deficient beta cells displayed normal glucose-induced changes in membrane potential and intracellular free Ca(2+), while granule docking and insulin secretion were enhanced. Conversely, betaAMPK transgenic mice were glucose-intolerant and displayed defective insulin secretion.
Conclusions/interpretation: Inhibition of AMPK activity within the beta cell is necessary, but not sufficient for stimulation of insulin secretion by glucose to occur. AMPK activation in extrapancreatic RIP2.Cre-expressing cells might also influence insulin secretion in vivo.
Figures
Similar articles
-
LKB1 deletion with the RIP2.Cre transgene modifies pancreatic beta-cell morphology and enhances insulin secretion in vivo.Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1261-73. doi: 10.1152/ajpendo.00100.2010. Epub 2010 Mar 30. Am J Physiol Endocrinol Metab. 2010. PMID: 20354156 Free PMC article.
-
Loss of AMP-activated protein kinase alpha2 subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia.Biochem J. 2010 Jul 15;429(2):323-33. doi: 10.1042/BJ20100231. Biochem J. 2010. PMID: 20465544 Free PMC article.
-
Rat insulin promoter 2-Cre recombinase mice bred onto a pure C57BL/6J background exhibit unaltered glucose tolerance.J Endocrinol. 2007 Sep;194(3):551-5. doi: 10.1677/JOE-07-0161. J Endocrinol. 2007. PMID: 17761894
-
The relevance of AMP-activated protein kinase in insulin-secreting β cells: a potential target for improving β cell function?J Physiol Biochem. 2019 Nov;75(4):423-432. doi: 10.1007/s13105-019-00706-3. Epub 2019 Nov 5. J Physiol Biochem. 2019. PMID: 31691163 Free PMC article. Review.
-
Role of AMPK in pancreatic beta cell function.Mol Cell Endocrinol. 2013 Feb 25;366(2):127-34. doi: 10.1016/j.mce.2012.06.020. Epub 2012 Jul 3. Mol Cell Endocrinol. 2013. PMID: 22766107 Review.
Cited by
-
Mitochondrial bioenergetics, metabolism, and beyond in pancreatic β-cells and diabetes.Front Mol Biosci. 2024 Feb 9;11:1354199. doi: 10.3389/fmolb.2024.1354199. eCollection 2024. Front Mol Biosci. 2024. PMID: 38404962 Free PMC article. Review.
-
Opposing effects on regulated insulin secretion of acute vs chronic stimulation of AMP-activated protein kinase.Diabetologia. 2022 Jun;65(6):997-1011. doi: 10.1007/s00125-022-05673-x. Epub 2022 Mar 16. Diabetologia. 2022. PMID: 35294578 Free PMC article.
-
Brain Permeable AMP-Activated Protein Kinase Activator R481 Raises Glycaemia by Autonomic Nervous System Activation and Amplifies the Counterregulatory Response to Hypoglycaemia in Rats.Front Endocrinol (Lausanne). 2021 Dec 17;12:697445. doi: 10.3389/fendo.2021.697445. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34975743 Free PMC article.
-
Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations.J Endocrinol Invest. 2022 Jan;45(1):95-103. doi: 10.1007/s40618-021-01620-6. Epub 2021 Jun 30. J Endocrinol Invest. 2022. PMID: 34191257 Free PMC article.
-
Mesoscopic Optical Imaging of the Pancreas-Revisiting Pancreatic Anatomy and Pathophysiology.Front Endocrinol (Lausanne). 2021 Mar 4;12:633063. doi: 10.3389/fendo.2021.633063. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33746904 Free PMC article. Review.
References
-
- Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ.Res. 2007;100:328–341. - PubMed
-
- KurthKraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5 ′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes. 1999;48:1667–1671. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
